PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Psoriasis: Condition overview • Prevalence • Economic burden of psoriasis PART 06: Pipeline analysis • Novel mechanisms targeted by pipeline candidates PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by type of molecule • Global biologics market • Small molecules PART 09: Market segmentation by mechanism of action • TNF inhibitors • PDE4 inhibitors • IL blockers • Others PART 10: Market segmentation by severity of disease • Mild psoriasis • Moderate psoriasis • Severe psoriasis PART 11: Market segmentation by ROA • Oral • Parenteral PART 12: Geographical segmentation • Systemic psoriasis therapeutics market in Americas • Systemic psoriasis therapeutics market in US • Systemic psoriasis therapeutics market in EMEA • Systemic psoriasis therapeutics market in APAC PART 13: Market drivers • Dominance of market by biologics • Increase in psoriatic patient pool due to new diagnostic procedures • Recurrence of psoriasis • Expected approval of late-stage pipeline molecules PART 14: Impact of drivers PART 15: Market challenges • Physician's reluctance to prescribe biosimilars • Innovative blue LED device and magnetic therapy as potential therapeutics substitutes • Unknown disease etiology • Use of CAM and topical drugs to treat psoriasis PART 16: Impact of drivers and challenges PART 17: Market trends • Advent of biologics with novel MOA and cell-based strategies • Emergence of next-generation systemic psoriatic therapies • Preference for combination therapies • Popularity of off-label systemic medications PART 18: Vendor landscape • Competitive scenario • Upcoming vendors • Key news • AbbVie • Johnson & Johnson • Celgene • Amgen • Pfizer • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Economic burden of psoriasis Exhibit 03: Annual treatment costs of psoriasis 2014 ($) Exhibit 04: Global systemic psoriasis therapeutics market: Pipeline portfolio Exhibit 05: Pipeline share of molecules in different stages of development 2015 Exhibit 06: Novel targets of pipeline candidates Exhibit 07: Share of novel pipeline molecules based on their MOA 2015 Exhibit 08: Approvals and patent expiries of top selling biologics Exhibit 09: Global systemic psoriasis therapeutics market 2015-2020 ($ billions) Exhibit 10: Global systemic psoriasis therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 11: A few patient assistance programs offered by various companies Impact of drivers and challenges on the market Exhibit 12: Impact of key customer segments on market 2015 Exhibit 13: Opportunities faced by psoriasis industry today Exhibit 14: Five forces analysis Exhibit 15: Global systemic psoriasis therapeutics market: Segmentation by type of molecule (2015-2020) Exhibit 16: Global systemic psoriasis therapeutics market: Segmentation by type of molecule 2015 Exhibit 17: Competitive assessment of marketed and late-stage pipeline molecules Exhibit 18: Global biologics market 2015-2020 ($ billions) Exhibit 19: Opportunity analysis of global systemic psoriasis therapeutics market by type of molecule Exhibit 20: Impact of biologics on various sectors Exhibit 21: Global small molecules market 2015-2020 ($ millions) Exhibit 22: Average percentage of patients receiving TNF inhibitors 2010 and 2015 Exhibit 23: Global systemic psoriasis therapeutics market segmentation by MOA 2015 Exhibit 24: Global systemic psoriasis therapeutics market segmentation by MOA 2020 Exhibit 25: Global systemic psoriasis therapeutics market segmentation by severity of disease 2015 Exhibit 26: Global systemic psoriasis therapeutics segmentation by ROA 2015 Exhibit 27: Global systemic psoriasis therapeutics market: Geographical outlook (2015-2020) Exhibit 28: Global systemic psoriasis therapeutics market: Geography outlook 2015 Exhibit 29: Revenue/growth outlook in different countries/regions 2015 Exhibit 30: Systemic psoriasis therapeutics market in Americas 2015-2020 ($ billions) Exhibit 31: Systemic psoriasis therapeutics market in America by country 2015 Exhibit 32: Systemic psoriasis therapeutics market in US 2015-2020 ($ billions) Exhibit 33: Systemic psoriasis therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 34: Systemic psoriasis therapeutics market in APAC 2015-2020 ($ billions) Exhibit 35: Global systemic psoriasis therapeutics market by geographical segmentation 2015 Exhibit 36: Global systemic psoriasis therapeutics market by geographical segmentation 2020 Exhibit 37: Global systemic psoriasis therapeutics market revenue by geography 2015-2020 ($ billions) Exhibit 38: Biologicals approvals by US FDA Exhibit 39: List of some pipeline molecules Exhibit 40: Impact of drivers Exhibit 41: Key reasons to prescribe biosimilars 2015 Exhibit 42: CAM and topical drugs for psoriasis Exhibit 43: Usage of CAMs in US 2014 Exhibit 44: Impact of drivers and challenges Exhibit 45: Psoriasis market: Impact assessment of top trends 2015 Exhibit 46: Market share of major vendors for global systemic psoriasis therapeutics market 2015 Exhibit 47: Competitive assessment of vendors Exhibit 48: Key vendors: Geographical presence 2015 Exhibit 49: YoY sales comparison of top selling drugs 2013-2015 ($ billions) Exhibit 50: Upcoming vendors Exhibit 51: AbbVie: Product segmentation by revenue 2015 Exhibit 52: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions) Exhibit 53: AbbVie: YoY revenue and growth rate of Humira (in US) 2013-2015 ($ billions) Exhibit 54: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions) Exhibit 55: AbbVie: Metrics analysis Exhibit 56: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions) Exhibit 57: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2013-2015 ($ billions) Exhibit 58: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions) Exhibit 59: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions) Exhibit 60: Johnson & Johnson: YoY growth rate and revenue of Stelara (in US) 2013-2015 ($ millions) Exhibit 61: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions) Exhibit 62: Johnson & Johnson: Metrics analysis Exhibit 63: Celgene: YoY revenue comparison of Otezla 2014-2015 ($ millions) Exhibit 64: Celgene: Metrics analysis Exhibit 65: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2013-2015 ($ billions) Exhibit 66: Amgen: YoY revenue and growth rate of Enbrel (in US) 2013-2015 ($ billions) Exhibit 67: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2013-2015 ($ millions) Exhibit 68: Amgen: Metrics analysis Exhibit 69: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions) Exhibit 70: Pfizer: Metrics analysis

AbbVie, Johnson & Johnson, Celgene, Amgen, Pfizer, AbGenomics, Almirall, Anacor Pharmaceuticals, ApoPharma, Astellas Pharma, AstraZeneca, Aurinia Pharmaceuticals, Biocon, Biogen Idec, Biotest, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite BioPharma, Cellceutix Corporation, Coherus Biosciences, Creabilis, Crescendo Biologics, Delenex Therapeutics, Dermira, Eli Lilly, F. Hoffmann-La Roche, Forward Pharma, G & W Laboratories, GlaxoSmithKline, Idera Pharmaceuticals, Incyte Corporation, Kadmon, kinetabio, KPI Therapeutics, Kyowa Hakko Kirin, LEO Pharma, Maruho, Merck, Mitsubishi Tanabe Pharma, Moleculin, MorphoSys, Novartis, Pfizer, Prism Pharma, Promius Pharma, Prothena Biosciences, Provectus Biopharmaceuticals, Sandoz, Sun Pharmaceuticals, Takeda Pharmaceuticals, Taro Pharmaceuticals, TFS Corp, Therapeutics, UCB, Valeant Pharmaceuticals, VBL Therapeutics, XenoPort, Ziarco Pharma.